AR030850A1 - METHODS TO MINIMIZE THE IMMUNE REJECTION OF A NUCLEAR TRANSFER FETUS - Google Patents
METHODS TO MINIMIZE THE IMMUNE REJECTION OF A NUCLEAR TRANSFER FETUSInfo
- Publication number
- AR030850A1 AR030850A1 ARP010104676A ARP010104676A AR030850A1 AR 030850 A1 AR030850 A1 AR 030850A1 AR P010104676 A ARP010104676 A AR P010104676A AR P010104676 A ARP010104676 A AR P010104676A AR 030850 A1 AR030850 A1 AR 030850A1
- Authority
- AR
- Argentina
- Prior art keywords
- embryo
- fetus
- mhc
- antigen
- nuclear transfer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se relaciona con un método para la minimizacion del rechazo inmunologico de un feto de transferencia nuclear ("TN"), que incluye transferir un embrion de TN a un recipiente de embriones, bajo condiciones efectivas para el desarrollo de un feto de TN, con mínimo riesgo de rechazo inmunologico del feto debido a una respuesta inmune materna anti-fetal de MHC-I. Luego de determinar un tipo de antígeno MHC-I para un embrion de TN y un tipo de antígeno MHC-I para recipientes de embriones, el embrion de TN es o bien (i) transferido a un primer recipiente de embriones que tiene un tipo de antígeno de MHC-I compatible, bajo condiciones eficaces para desarrollo de un feto de TN a partir del embrion de TN, o (ii) transferido a un segundo recipiente de embriones que tiene un tipo de antígeno de MHC-I incompatible, seguido de la regulacion de la expresion MHC-I del embrion de TN, o de la supresion de una respuesta inmune del recipiente de embriones, bajo condiciones eficaces para el desarrollo de un feto de transferencia nuclear.This relates to a method for minimizing the immunological rejection of a nuclear transfer fetus ("TN"), which includes transferring a TN embryo to an embryo vessel, under conditions effective for the development of a TN fetus, with minimal risk of immunological rejection of the fetus due to a maternal anti-fetal immune response of MHC-I. After determining a type of MHC-I antigen for a TN embryo and a type of MHC-I antigen for embryo vessels, the TN embryo is either (i) transferred to a first embryo container that has a type of compatible MHC-I antigen, under effective conditions for the development of a TN fetus from the TN embryo, or (ii) transferred to a second embryo vessel having an incompatible type of MHC-I antigen, followed by the regulation of the MHC-I expression of the TN embryo, or the suppression of an immune response from the embryo vessel, under conditions effective for the development of a nuclear transfer fetus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23767300P | 2000-10-03 | 2000-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030850A1 true AR030850A1 (en) | 2003-09-03 |
Family
ID=22894696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104676A AR030850A1 (en) | 2000-10-03 | 2001-10-03 | METHODS TO MINIMIZE THE IMMUNE REJECTION OF A NUCLEAR TRANSFER FETUS |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR030850A1 (en) |
| AU (1) | AU2001296528A1 (en) |
| WO (1) | WO2002029000A2 (en) |
-
2001
- 2001-10-03 AU AU2001296528A patent/AU2001296528A1/en not_active Abandoned
- 2001-10-03 WO PCT/US2001/030925 patent/WO2002029000A2/en not_active Ceased
- 2001-10-03 AR ARP010104676A patent/AR030850A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002029000A2 (en) | 2002-04-11 |
| WO2002029000A3 (en) | 2003-02-27 |
| AU2001296528A1 (en) | 2002-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Glant et al. | Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans | |
| Murgita | The immunosuppressive role of alpha‐fetoprotein during pregnancy | |
| Summerskill | Chronic active liver disease reexamined: prognosis hopeful | |
| Talbot et al. | Morphological features of the acrosome reaction of lobster (Homarus) sperm and the role of the reaction in generating forward sperm movement | |
| ATE26167T1 (en) | LIGHTER, ESPECIALLY DISPOSABLE LIGHTER. | |
| Clark et al. | Presence and incidence of izumo antibodies in sera of immunoinfertile women and men | |
| Michael et al. | Appearance of regional surface autoantigens during spermatogenesis: comparison of anti-testis and anti-sperm autoantisera | |
| Leeksma et al. | The platelet alloantigen Zwa or PlA1 is expressed by cultured endothelial cells | |
| AR030850A1 (en) | METHODS TO MINIMIZE THE IMMUNE REJECTION OF A NUCLEAR TRANSFER FETUS | |
| BR0208717A (en) | Apparatus for transferring liquid metals from a collecting container to a receiving container | |
| Gleicher | Autoantibodies in infertility: current opinion | |
| Tsunoda et al. | Reproduction in rats and mice isoimmunized with homogenates of ovary or testis with epididymis, or sperm suspensions | |
| ALLEGRUCCI et al. | Circulating human antisperm antibodies recognize prostasomes | |
| Zauli et al. | Antibodies to the cytoskeleton components and other autoantibodies in inflammatory bowel disease | |
| Villarroya et al. | Regional heterogeneity of human spermatozoa detected with monoclonal antibodies | |
| Ulčová‐Gallová et al. | Does in vitro fertilization (IVF) influence the levels of sperm and zona pellucida (ZP) antibodies in infertile women? | |
| DE3782429D1 (en) | DRINKING TANK, ESPECIALLY FOR ESPRESSO. | |
| Pinchera et al. | Cellular localization of the microsomal antigen and the thyroid peroxidase antigen | |
| Yamashita et al. | Effect of endocrine disrupters on immune responses in vivo | |
| Sepetjian et al. | Investigation of a specific IgM antibody test in neonatal congenital syphilis | |
| BR112023024231A2 (en) | HYPOIMMUNOGENIC RHD NEGATIVE PRIMARY T CELLS | |
| Hekman et al. | Antibodies to spermatozoa. III. Responses in rabbits and guinea-pigs to immunization with guinea-pig sperm cells | |
| Fujimoto et al. | Autoantibodies to the heat-shock protein hsp73 in localized scleroderma | |
| Bradley | Evidence and certainty in Lisu | |
| Martin | The present indicative in the eschatological statements of 1 Peter 1: 6, 8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |